Who
Jeffrey Poulton V
Director
Company insider
Files Form 4 as: Director, CervoMed; EVP, Chief Financial Officer, Alnylam Pharmaceuticals; Director, Leverage Shares 2X Long FIX Daily ETF.
In numbers
- Trades disclosed
- 219
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $11.8M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 10 Oct 2019
- Last trade
- 8 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jun 2026filed 10 Jun 2026 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,150 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | CRVO CervoMedoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,150 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $36K114 at $319.03 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $35K109 at $320.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $74K230 at $320.81 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $99K309 at $321.82 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $121K374 at $323.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $265K818 at $323.84 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $95K291 at $324.88 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $73K223 at $325.67 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $36K114 at $319.03 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $35K109 at $320.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $74K230 at $320.81 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $99K309 at $321.82 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $121K374 at $323.01 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $265K818 at $323.84 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $95K291 at $324.88 | filing |
| 4 Mar 2026filed 6 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $73K223 at $325.67 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,769 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $43K129 at $331.93 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) and TScan Therapeutics (NASDAQ:TCRX) Critical SurveyALNY · themarketsdaily.com · 20 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyALNY · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Jeffrey Poulton V; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.